Innovation and Advances in Peritoneal Oncology
In the latest episode of Viamed Talks, Dr. Delia Cortés Guiral, director of the Viamed Institute of Oncological Surgery (IVOQA), shares the significant advancements that the institute has achieved in just two years. IVOQA has established itself as a leader in advanced oncological surgery, focusing on introducing pioneering techniques for the treatment of peritoneal oncology in Spain.
During the discussion, the impact of cytoreductive surgery and HIPEC in revolutionizing the treatment of peritoneal carcinomatosis is highlighted. This condition, which had virtually no treatment options two decades ago, now allows patients an average survival of nearly five years, with 16% achieving complete cure.
Additionally, the use of innovative techniques such as PIPAC and EPIPAC is addressed, designed for patients with inoperable cancers due to their advanced stage. These techniques allow chemotherapy to be administered directly into the abdomen, improving quality of life without the common adverse effects of traditional chemotherapy. IVOQA also participates in international clinical trials, including the use of intraperitoneal nanoparticles, a treatment in which it is a pioneer in Spain.
Dr. Cortés emphasizes the importance of a comprehensive approach in treating advanced cancer patients, from prehabilitation prior to surgery to the implementation of a therapeutic garden in the hospital. This space is designed to enhance the physical and emotional well-being of patients during their treatments.
Finally, collaboration with multinational companies in the field of medical research is marking a turning point for Viamed, opening new possibilities for patients by providing access to the latest treatments available worldwide.